Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse.

作者: Sarah McClelland , Meinrad Gawaz , Elisabeth Kennerknecht , Carolin Sophie Ildiko Konrad , Susanne Sauer

DOI: 10.1016/J.ATHEROSCLEROSIS.2008.04.016

关键词:

摘要: Abstract Objective Prostaglandin and thromboxane (TXA 2 ) generation is increased in atherosclerosis. Studies with selective inhibitors attribute the enhanced prostacyclin (PGI to both cyclooxygenase-1 (COX-1) COX-2 whereas TXA reflects platelet COX-1 expression. However, formation remains elevated patients cardiovascular disease on doses of aspirin that fully suppress COX-1, suggesting other tissue sources for formation. Disruption receptor gene suppresses development Notwithstanding this, role atherosclerosis unclear, as it widely distributed contributes a number products, including those potentially contribute resolution inflammation. Methods results We examined prostaglandin generation, platelet–vessel wall interactions apoE −/− murine model by disrupting gene. ApoE /COX-1 +/+ , +/− were administered 1% cholesterol diet 8 weeks. Stable urinary metabolites PGI which markedly reduced disruption COX-1. Deletion one or copies suppressed lesion Assessment intravital microscopy showed significant decrease firm adhesion platelets apoE/COX-1 double knockout (DKO). Conclusion atherosclerosis, disease. Non-platelet are inaccessible standard may

参考文章(36)
Domenico Praticò, Tillmann Cyrus, Hongwei Li, Garret A. FitzGerald, Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood. ,vol. 96, pp. 3823- 3826 ,(2000) , 10.1182/BLOOD.V96.12.3823
Robert J. Clarke, Gail Mayo, Patricia Price, Garret A. FitzGerald, Suppression of Thromboxane A2but Not of Systemic Prostacyclin by Controlled-Release Aspirin New England Journal of Medicine. ,vol. 325, pp. 1137- 1141 ,(1991) , 10.1056/NEJM199110173251605
Francesca Catella-Lawson, Muredach P. Reilly, Shiv C. Kapoor, Andrew J. Cucchiara, Susan DeMarco, Barbara Tournier, Sachin N. Vyas, Garret A. FitzGerald, Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin The New England Journal of Medicine. ,vol. 345, pp. 1809- 1817 ,(2001) , 10.1056/NEJMOA003199
Francesca Catella, Garret A. Fitzgerald, Paired analysis of urinary thromboxane B2 metabolites in humans Thrombosis Research. ,vol. 47, pp. 647- 656 ,(1987) , 10.1016/0049-3848(87)90103-4
Marta L. Capone, Maria G. Sciulli, Stefania Tacconelli, Marilena Grana, Emanuela Ricciotti, Giulia Renda, Patrizia Di Gregorio, Gabriele Merciaro, Paola Patrignani, Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects Journal of the American College of Cardiology. ,vol. 45, pp. 1295- 1301 ,(2005) , 10.1016/J.JACC.2005.01.045
Karine M Egan, Miao Wang, Margaret B Lucitt, Alicia M Zukas, Ellen Puré, John A Lawson, Garret A FitzGerald, None, Cyclooxygenases, Thromboxane, and Atherosclerosis Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism Circulation. ,vol. 111, pp. 334- 342 ,(2005) , 10.1161/01.CIR.0000153386.95356.78
Nassia Methia, Patrick André, Cécile V. Denis, Maria Economopoulos, Denisa D. Wagner, Localized reduction of atherosclerosis in von Willebrand factor–deficient mice Blood. ,vol. 98, pp. 1424- 1428 ,(2001) , 10.1182/BLOOD.V98.5.1424
Vladimir R. Babaev, Lei Ding, Jeff Reese, Jason D. Morrow, Matthew D. Breyer, Sudhansu K. Dey, Sergio Fazio, MacRae F. Linton, Cyclooxygenase-1 Deficiency in Bone Marrow Cells Increases Early Atherosclerosis in Apolipoprotein E– and Low-Density Lipoprotein Receptor–Null Mice Circulation. ,vol. 113, pp. 108- 117 ,(2005) , 10.1161/CIRCULATIONAHA.105.591537
F. M. PULCINELLI, S. RIONDINO, A. CELESTINI, P. PIGNATELLI, E. TRIFIRO, L. DI RENZO, F. VIOLI, Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin. Journal of Thrombosis and Haemostasis. ,vol. 3, pp. 2784- 2789 ,(2005) , 10.1111/J.1538-7836.2005.01633.X